Unleashing nature’s manufacturing powerhouse.
B cells are nature’s exquisitely tuned medicine factories, manufacturing proteins to fight disease and maintain health. What if… we could engineer these cells to produce any therapeutic protein needed … allogeneically, without preconditioning, and redosably? The resulting new class of medicines – Engineered B Cell Medicines (BCMs) – could be transformative.
Powerful & Durable
In nature, a single B cell can produce thousands of proteins per second at constant levels over decades. Leveraging this inherent power, our BCMs could create previously impossible options for patients.
B cells resist interference by outside agents and have been notoriously intractable to therapeutically relevant engineering. Until now. Our tunable, site-specific, precision genome engineering results in BCMs that produce proteins efficiently, with controlled, constant and consistent dosing (and redosing).
Plasma cells, terminally differentiated B cells, have evolved to be able to more easily evade immune detection, and they intrinsically traffic to and engraft in the bone marrow. These properties drive the potential for powerful off-the-shelf medicines without the need for the toxic preconditioning required in other classes of cellular medicine.
BCMs can be engineered to produce a vast array of therapeutically important biologics without the burdens of other cellular medicines, driving exceptionally broad therapeutic application — across protein classes, patient populations, and therapeutic areas.
Keystone Symposia on Emerging Cellular Therapies|January 24, 2024
Development of an Ex Vivo Precision Gene Engineered B Cell Medicine Platform that Produces Active and Sustained Levels of Therapeutic Proteins with Broad Utility
ASH 2023|December 10, 2023